Trial reportLeukemia2015
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.
Abstract readClinical Trial, Phase IIILetterRandomized Controlled Trial
In one paragraph
Trial report in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.The Lancet. Haematology · 2017Trial
- Article
- Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.Blood · 2025Review
- Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.Innovation (Cambridge (Mass.)) · 2024Article
- Article
- The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia CarryingCancers · 2022Article
- A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms.Cancer research communications · 2022Article
- Drug responsiveness of leukemic cells detected in vitro at diagnosis correlates with therapy response and survival in patients with acute myeloid leukemia.Cancer reports (Hoboken, N.J.) · 2021Observational
- Article
- Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia.International journal of molecular sciences · 2020Review
- CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia.Frontiers in genetics · 2020Article
- Article
- Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.Blood advances · 2019Article
- Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.Bone marrow transplantation · 2019Article
- Refining AML outcome prediction.Leukemia · 2019Article
- Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation.Leukemia · 2019Article
- Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.Hematology. American Society of Hematology. Education Program · 2018Review
- Can we forecast induction failure in acute myeloid leukemia?Haematologica · 2018Article
- A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.Haematologica · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
R B WalterClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M OthusPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
E M PaiettaDepartment of Oncology, Montefiore Medical Center-North Division, Albert Einstein College of Medicine, Bronx, NY, USA.
J RacevskisDepartment of Oncology, Montefiore Medical Center-North Division, Albert Einstein College of Medicine, Bronx, NY, USA.
H F FernandezDepartment of Blood and Marrow Transplant, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
J-W LeeDepartment of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA.
Z SunDepartment of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA.
M S TallmanLeukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
J PatelHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
M GönenDepartment of Epidemiology and Biostatistics Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
O Abdel-WahabLeukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
R L LevineLeukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
E H EsteyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6MSWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MECOG Statistical Office Data Management GrantU10CA066636 · NCI · FRONTIER SCI &TECHNOLOGY RSCH FDN, INC · PI GRAY, ROBERT J · 1994 to 2013
$39.5MPROVIDE STATISTICAL SERVICESU10CA023318 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRAY, ROBERT J · 1985 to 2013
$33.4MMontefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8MRole of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2MECOG Clinical TrialsU10CA017145 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BENSON, AL B · 1985 to 2013
$6.1MNetwork Lead Academic Participating Site: Memorial Sloan-Kettering Cancer CenterU10CA180791 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AGHAJANIAN, CAROL, MORRIS, MICHAEL J · 2014 to 2018
$4.6MNCI NIH HHS CA180791NCI NIH HHS CA180794NCI NIH HHS CA180820NCI NIH HHS CA180867NCI NIH HHS CA189859NCI NIH HHS R01 CA090998NCI NIH HHS R01-CA090998-09NCI NIH HHS R01 CA173636NCI NIH HHS R21 CA182010NCI NIH HHS R21-CA182010NCI NIH HHS U10 CA014958NCI NIH HHS U10 CA017145NCI NIH HHS U10 CA021115NCI NIH HHS U10 CA023318NCI NIH HHS U10 CA066636NCI NIH HHS U10 CA073590NCI NIH HHS U10 CA180791NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180827NCI NIH HHS U24 CA196172
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene Expression ProfilingAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCohort StudiesCytarabineDaunorubicinDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm Recurrence, LocalBiomarkers, TumorCytarabineDaunorubicin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.